Scale -


  • Revenue is 235 Rs Cr; Annual Growth is 19 %; Continuous Growth over 3 years; 5 Year CAGR is 20 %
  • PAT is 29.5 Rs Cr; Annual Growth is 18 %; Continuous Growth over 3 years; 5 Year CAGR is 48 %
  • Ebitda is 47.83 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 38 %
  • PBT is 3.86 Rs Cr; 5 Year CAGR is 42 %
  • Quarterly Revenue is 44.88 Rs Cr; in Bottom Quartile

Profitability -


  • PBDIT Margin is 20.31 %; 5 Year CAGR is 15 %
  • PAT Margin is 12.52 %; 5 Year CAGR is 23 %

Return -


  • ROA is 6.59 %; 5 Year CAGR is 17 %; Annual Decline is -23 %
  • ROE is 10.78 %; 5 Year CAGR is 19 %
  • ROCE is 13.15 %; Annual Decline is -24 %

Efficiency -


  • Operating cash flow is 23.96 Rs Cr; Annual Growth is 37 %; Continuous Growth over 3 years; 5 Year CAGR is 43 %
  • Inventory Turnover Ratio is 17.55; in Top Quartile; Continuous Decline over 3 years
  • Current Ratio is 1.83; Continuous Decline over 3 years
  • Quick Ratio is 1.73; Continuous Decline over 3 years

Solvancy -


  • Debt/Equity is 0.32; Annual Growth is 33 %; Continuous Growth over 3 years; 5 Year CAGR is 21 %
  • Long term Debt is 58.6 Rs Cr; Annual Growth is 111 %; Continuous Growth over 3 years; in Top Quartile
  • Total Debt is 88.71 Rs Cr; Annual Growth is 80 %; Continuous Growth over 3 years; 5 Year CAGR is 44 %

Quality -


  • Operating cashflow/ebitda is 50 %; Annual Growth is 22 %; Continuous Growth over 3 years
  • Operating cashflow/PAT is 81 %; Continuous Growth over 3 years
  • Current Tax/PAT is 37 %; Continuous Decline over 3 years; in Top Quartile
  • Other Expenses/Total Expenses is 28 %; Continuous Decline over 3 years; in Top Quartile
  • Change in Inventories/Total Expenses is 1 %; Annual Growth is 177 %
  • Exceptional Items/PBT is 0 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
India’s Kilitch Drugs to Sell Ethiopian Pharmaceutical Plant for $14 Million
Kilitch Drugs to sell Ethiopian subsidiary for $14 million as it bets on India expansion & GLP-1 growth
Kilitch Drugs KILITCH Divests Ethiopian Unit for US$14 Million
Kilitch Drugs to divest entire stake in its Ethiopian subsidiary for $14 million
Kilitch Drugs ?? ???? ??????! ??????????? ????? ????? ?????? **$12.85 ??????**
Kilitch Drugs India NE Director Venkita Subramanian Rajan exits board
Kilitch Drugs KILITCH Ethiopia subsidiary divestment USD 14M
Kilitch Drugs to Divest Ethiopian Subsidiary for USD 12.85 Million
Kilitch Drugs: ?????????? ??????? ?????? ?????, **$12.85 ??????** ?? ??? ???
Kilitch Drugs: ????????????????? ?????? ???????! **$12.85 ?????????** ???????? ?????????
Kilitch Drugs KILITCH Independent Director Resignation Oct 2026
Kilitch Drugs (India) Ltd. Share Price Rise Streak and